Drug Profile
Research programme: anticancer therapeutics - Galaxy Biotech
Alternative Names: Anti-DR4 mAbs; Anti-DR5 mAbs; Anti-FGF2 mAbs; Anti-FGFR2 mAbs; Bispecific antibodies of DR-4 mAbs; Bispecific antibodies of DR-5 mAbs; GAL-F2; GAL-F2 mAb; GAL-F21 mAb; GAL-FR21; HuD-114; HuG-4.2; HuGAL-F2; HuGAL-FR21Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Galaxy Biotech
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Death domain receptor agonists; Fibroblast growth factor inhibitors; Fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 20 Jun 2011 Research programme: anticancer monoclonal antibodies - Galaxy Biotech is available for licensing as of 20 Jun 2011. http://galaxybiotech.com
- 06 Apr 2011 Preclinical pharmacodynamics data in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (102nd-AACR-2011) ,